In the last fifty years, pharmaceutical companies have spent tens of billions of dollars trying to find new classes of antibiotic drugs. Only one has made it into clinical practice. Seem surprising to you? Yeah, me too. At the same time, antibacterial resistance has been rising, meaning the pathogens that infect us are getting better ...